Subjects |
196 |
252 |
1214 |
|
Age at starting LTOT years |
77.5±8.2 |
76.1±8.9 |
76.3±8.8 |
0.156 |
Female |
89 (45.4) |
123 (48.8) |
415 (34.2) |
<0.001 |
FEV1% pred# |
66.3±37.3 |
67.0±39.7 |
71.6±40.3 |
0.106 |
VC % pred# |
54.7±34.2 |
56.2±35.6 |
60.4±34.7 |
0.052 |
FEV1/VC# |
0.9±0.3 |
0.9±0.3 |
0.8±0.4 |
0.427 |
PaO2呼吸空气#kPa |
6.5±1.0 |
6.6±1.0 |
6.6±1.0 |
0.441 |
PaCO2呼吸空气#kPa |
5.3±1.0 |
5.3±1.0 |
5.1±0.9 |
<0.001 |
PaO2breathing oxygen#kPa |
5.7±0.9 |
5.7±1.0 |
5.4±1.0 |
0.001 |
Smoking status |
|
|
|
|
Never-smoker |
61 (31.1) |
66 (26.2) |
338 (27.8) |
0.797 |
Ex-smoker |
1 (1.0) |
3 (1.2) |
9 (0.7) |
|
Ex-/current smoker |
105 (53.6) |
149 (59.1) |
698 (57.5) |
|
Missing |
30 (15.31) |
37 (14.7) |
178 (14.7) |
|
BMI¶kg·m−2 |
|
|
|
|
<18.5 |
10 (5.1) |
12 (4.8) |
35 (2.9) |
0.579 |
18.5–24.9 |
107 (54.6) |
143 (56.8) |
707 (58.2) |
|
25–29.9 |
53 (27.0) |
67 (26.6) |
314 (25.9) |
|
≥30 |
26 (13.3) |
30 (11.9) |
158 (13.0) |
|
WHO Performance Status |
|
|
|
|
0–1 |
76 (38.8) |
93 (36.9) |
566 (46.6) |
<0.001 |
2 |
54 (27.6) |
70 (27.8) |
350 (28.8) |
|
3–4 |
49 (25.0) |
60 (23.8) |
161 (13.3) |
|
Missing |
17 (8.7) |
29 (11.5) |
137 (11.3) |
|
Hospitalisations within 4 years before baseline |
4 (2–6) |
4 (2–6) |
2 (1–4) |
<0.001 |
Hospitalised days out of the 91 days before baseline |
14 (5.5–24) |
15 (8–27) |
11.5(4–21) |
<0.001 |
Follow-up time hospitalised (follow-up time/hospitalised days) % |
7.6 (2.3–20.3) |
8.4 (2.6–19.8) |
6.2 (2.1–16.8) |
0.175 |
Cardiovascular diseases n |
|
|
|
|
0 |
45 (23.0) |
59 (23.4) |
416 (34.3) |
<0.001 |
1 |
3 (1.5) |
3 (1.2) |
58 (4.8) |
|
2 |
65 (33.2) |
68 (27.0) |
300 (24.7) |
|
≥3 |
83 (42.4) |
122 (48.4) |
440 (36.2) |
|
Comorbidity |
|
|
|
|
COPD |
50 (25.5) |
67 (26.4) |
234 (19.3) |
0.010 |
Cancer |
81 (41.3) |
107 (42.5) |
417 (34.4) |
0.016 |
Depression/anxiety |
43 (21.9) |
33 (13.1) |
37 (3.1) |
<0.001 |
Diabetes mellitus |
44 (22.5) |
73 (29.0) |
219 (18.0) |
<0.001 |
Injury |
33 (16.8) |
54 (21.4) |
154 (12.7) |
<0.001 |
Osteoporosis |
11 (5.6) |
35 (13.9) |
47 (3.9) |
<0.001 |
Renal failure |
18 (9.2) |
25 (9.9) |
65 (5.4) |
0.007 |
Pulmonary hypertension |
12 (6.1) |
24 (9.5) |
86 (7.1) |
0.315 |
GORD |
12 (6.1) |
18 (7.1) |
37 (3.1) |
0.003 |
BDZs |
|
|
|
|
High (>15 mg·day−1oral oxazepam equivalent) |
65 (33.2) |
27 (10.7) |
|
|
Low (≤15 mg·day−1oral oxazepam equivalent) |
131 (66.8) |
32 (12.7) |
|
|
Opioids |
|
|
|
|
High (>30 mg·day−1oral morphine equivalent) |
33 (16.8) |
122 (48.4) |
|
|
Low (≤30 mg·day−1oral morphine equivalent) |
27 (13.8) |
130 (51.6) |
|
|
Oral corticosteroids |
107 (54.6) |
135 (53.6) |
603 (49.7) |
0.284 |
Azathioprine |
8 (4.1) |
13 (5.2) |
89 (7.3) |
0.142 |
N-acetylcysteine |
81 (41.3) |
76 (30.2) |
372 (30.6) |
0.010 |